Compare Cassava Sciences Inc (FLNA) vs T1 Energy Inc. Common Stock (TE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs T1 Energy Inc. Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while T1 Energy Inc. Common Stock trades at $2.74 (market cap $868.55M). The key difference: T1 Energy Inc. Common Stock is far larger — about 24.6× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (251,946 versus 19,771,934). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| FLNA | TE | |
|---|---|---|
Market Cap | $35.34M | $868.55M |
Volume | 251,946 | 19,771,934 |
Sector | Health | Industrials |
52-Week High | $4.64 | $12.04 |
52-Week Low | $0.68 | $2.72 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$47.34M | $1.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite recent positive FDA news lifting a clinical hold on its epilepsy drug. The company shows improving quarterly EPS beats but remains unprofitable with negative cash flows. Analyst consensus is strongly bullish with 8 buy ratings versus 4 holds.
The outlook hinges on clinical progress—FDA clearance enables Phase 2a trials in 2027, a key catalyst. Risks include sustained cash burn and fiduciary concerns highlighted in recent news. Investors should weigh the high analyst optimism against fundamental weaknesses and regulatory execution risks.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →
